title: Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab.
abstract: The aggregation of biotherapeutics is a major hindrance to the development of successful drug candidates; however, the propensity to aggregate is often identified too late in the development phase to permit modification to the protein's sequence. Incorporating rational design for the stability of proteins in early discovery has numerous benefits. We engineered out aggregation-prone regions on the Fab domain of a therapeutic monoclonal antibody, bevacizumab, to rationally design a biobetter drug candidate. With the purpose of stabilizing bevacizumab with respect to aggregation, 2 strategies were undertaken: single point mutations of aggregation-prone residues and engineering a glycosylation site near aggregation-prone residues to mask these residues with a carbohydrate moiety. Both of these approaches lead to comparable decreases in aggregation, with an up to 4-fold reduction in monomer loss. These single mutations and the new glycosylation pattern of the Fab domain do not modify binding to the target. Biobetters with increased stability against aggregation can therefore be generated in a rational manner, by either removing or masking the aggregation-prone region or crowding out protein-protein interactions.
authors.affiliation: a Chemical Engineering ; Massachusetts Institute of Technology ; Cambridge , Massachusetts 02139.
authors.forename: Fabienne
authors.initials: F
authors.lastname: Courtois
authors.affiliation: a Chemical Engineering ; Massachusetts Institute of Technology ; Cambridge , Massachusetts 02139.
authors.forename: Neeraj J
authors.initials: NJ
authors.lastname: Agrawal
authors.affiliation: a Chemical Engineering ; Massachusetts Institute of Technology ; Cambridge , Massachusetts 02139.
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Lauer
authors.affiliation: a Chemical Engineering ; Massachusetts Institute of Technology ; Cambridge , Massachusetts 02139.
authors.forename: Bernhardt L
authors.initials: BL
authors.lastname: Trout
mesh_terms: D020816:Amino Acid Motifs; D000068258:Bevacizumab / Q000096:biosynthesis / Q000737:chemistry* / Q000235:genetics*; D002460:Cell Line; D006801:Humans; D066329:Protein Aggregates; D015202:Protein Engineering / Q000379:methods*
chemical_list: D066329:Protein Aggregates; D000068258:Bevacizumab
keywords: aggregation; bevacizumab; biobetter; glycosylation; monoclonal antibody; protein engineering; spatial aggregation propensity; stability